Probiotics in the prevention of traveller's diarrhoea

Not Applicable

Completed

• Conditions: Traveller's diarrhoea, prebiotics, lactobacillus, bifidobacterium; Infections and Infestations; traveller's diarrhoea

• Registration Number: ISRCTN76793515
• Lead Sponsor: Academic Medical Centre (AMC) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-02-26
• Study Completion: 2007-11-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 800

Inclusion Criteria

1. Both male and female adults (+18)
2. Travelling to high risk area's for Traveller's Diarrhoea (TD) (Middle East, Asia, South and Central America, North Africa)
3. Duration of travelling: min. seven days, max. 28 days
4. People who experienced TD before
5. All new travellers to high risk areas

Exclusion Criteria

1. Use of antibiotics until two weeks before leaving
2. Use of laxatives, acid blockers and diarrhoea inhibitors
3. Persons who already have complaints about their stomach and/or intestines
4. Irritable Bowel Syndrome (IBS)/Irritable Bowel Disease (IBD) and stoma patients
5. Pregnant or breastfeeding women
6. Patients with a serious disturbed or fragile/weak immune system (according to the Dutch National Coordination Center for Travelers' Health Advice [LCR] criteria)
7. Use of probiotics two weeks before start of journey
8. Frequent traveller's to high risk area's who never had TD complaints

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Consistency of stools according to Bristol scale<br> 2. Frequency of stools<br>

Secondary Outcome Measures

Name	Time	Method
Duration of traveller's diarrhoea